Skip to main content Accessibility help
×
Hostname: page-component-848d4c4894-ndmmz Total loading time: 0 Render date: 2024-04-30T11:04:04.515Z Has data issue: false hasContentIssue false

Chapter 27 - The use of botulinum neurotoxin in musculoskeletal pain and arthritis

Published online by Cambridge University Press:  05 February 2014

Jasvinder A. Singh
Affiliation:
Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA, and Mayo Clinic College of Medicine, Rochester, MN, USA
Daniel Truong
Affiliation:
The Parkinson’s and Movement Disorders Institute, Fountain Valley, California
Dirk Dressler
Affiliation:
Department of Neurology, Hannover University Medical School
Mark Hallett
Affiliation:
George Washington University School of Medicine and Health Sciences, Washington, DC
Christopher Zachary
Affiliation:
Department of Dermatology, University of California, Irvine
Get access

Summary

Prevalence and impact of arthritis

Arthritis affects nearly 50 million adults in the USA and is projected to increase in prevalence to 67 million adults, or 25% of those aged 18 years and older, by the year 2030 (Centers for Disease Control and Prevention, 2010a).

Arthritis is associated with significant healthcare and cost burden on society. In the USA alone, arthritis results in about 1 million annual hospitalizations (Helmick et al., 2008) and 44 million annual outpatient visits (American Academy of Orthopedic Surgeons, 2008). In 2003, the total cost of arthritis was $128 billion in the USA, including $81 billion in direct medical costs and $47 billion in indirect costs (lost earnings) (Centers for Disease Control and Prevention, 2007). Osteoarthritis alone is responsible for between $3.4 and $13.2 billion job-related costs each year (Buckwalter et al., 2004; Centers for Disease Control and Prevention, 2010b). Consequently, arthritis constitutes a public health problem associated with significant socioeconomic burden.

Osteoarthritis is the most common type of non-inflammatory arthritis that affects the aging population, but it can also present at a younger age in those with trauma or obesity. It primarily affects hands, knees and hips but can be generalized and affect other joint areas. It is characterized by cartilage lesions leading to symmetric narrowing of joint space, overproduction of bone leading to osteophytes and bony deformities. Inflammatory arthritis is characterized by swelling of the joint lining, which leads to joint destruction and bony erosions when not optimally treated. Two common types of inflammatory arthritis are rheumatoid arthritis and gout, which have predilection for different joints and have a different pathophysiology. Both are also associated with significant joint swelling, warmth and tenderness.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2014

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Academy of Orthopedic Surgeons (2008).United States Bone and Joint Decade: The Burden of Musculoskeletal Diseases in the United States. Rosemont, IL: American Academy of Orthopedic Surgeons.Google Scholar
Blersch, W, Schulte-Mattler, WJ, Przywara, S et al. (2002). Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study. J Neurol Sci, 205, 59–63.CrossRefGoogle ScholarPubMed
Boon, AJ, Smith, J, Dahm, DL et al. (2010). Efficacy of intra-articular botulinum toxin type A in painful knee osteoarthritis: a pilot study. PM R, 2, 268–76.CrossRefGoogle ScholarPubMed
Buckwalter, JA, Saltzman, C, Brown, T (2004). The impact of osteoarthritis: implications for research. Clin Orthop Relat Res, 427(Suppl), S6–15.CrossRefGoogle Scholar
Centers for Disease Control and Prevention (2007). National and state medical expenditures and lost earnings attributable to arthritis and other rheumatic conditions: United States, 2003. MMWR, 56, 4–7.Google Scholar
Centers for Disease Control and Prevention (2010a). Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation: United States, 2007–2009. MMWR, 59, 1261–5.Google Scholar
Centers for Disease Control and Prevention (2010b). Arthritis Foundation. A National Public Health Agenda for Osteoarthritis. Atlanta, GA: Centers for Disease Control and Prevention (, accessed 24 May 2013).Google Scholar
Freund, B, Schwartz, M, Symington, JM (1999). The use of botulinum toxin for the treatment of temporomandibular disorders: preliminary findings. J Oral Maxillofac Surg, 57, 916–20; discussion 920–1.CrossRefGoogle ScholarPubMed
Freund, B, Schwartz, M, Symington, JM (2000). Botulinum toxin: new treatment for temporomandibular disorders. Br J Oral Maxillofac Surg, 38, 466–71.CrossRefGoogle ScholarPubMed
Ge, Z, Hu, Y, Heng, BC et al. (2006). Osteoarthritis and therapy. Arthritis Rheum. 55, 493–500.CrossRefGoogle ScholarPubMed
Hayton, MJ, Santini, AJ, Hughes, PJ et al. (2005). Botulinum toxin injection in the treatment of tennis elbow. A double-blind, randomized, controlled, pilot study. J Bone Joint Surg Am, 87, 503–7.CrossRefGoogle ScholarPubMed
Helmick, CG, Felson, DT, Lawrence, RC et al. (2008). Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 58, 15–25.CrossRefGoogle ScholarPubMed
Keizer, SB, Rutten, HP, Pilot, P et al. (2002). Botulinum toxin injection versus surgical treatment for tennis elbow: a randomized pilot study. Clin Orthop Relat Res. 125–31.CrossRefGoogle ScholarPubMed
Kramer, HH, Angerer, C, Erbguth, F, Schmelz, M, Birklein, F. (2003). Botulinum toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. J Neurol, 250, 188–93.Google ScholarPubMed
Mahowald, ML, Singh, JA, Dykstra, D (2006). Long term effects of intra-articular botulinum toxin A for refractory joint pain. Neurotox Res. 9, 179–88.CrossRefGoogle ScholarPubMed
Mahowald, ML, Krug, HE, Singh, JA, Dykstra, D (2009). Intra-articular Botulinum toxin type A: a new approach to treat arthritis joint pain. Toxicon. 54, 658–67.CrossRefGoogle ScholarPubMed
Marchini, C, Acler, M, Bolognari, MA et al. (2010). Efficacy of botulinum toxin type A treatment of functional impairment of degenerative hip joint: Preliminary results. J Rehabil Med, 42, 691–3.Google ScholarPubMed
Morre, HH, Keizer, SB, van Os, JJ (1997). Treatment of chronic tennis elbow with botulinum toxin. Lancet, 349, 1746.CrossRefGoogle ScholarPubMed
Neugebauer, V, Lucke, T, Schaible, HG (1993). N-Methyl-d-aspartate (NMDA) and non-NMDA receptor antagonists block the hyperexcitability of dorsal horn neurons during development of acute arthritis in rat’s knee joint. J Neurophysiol, 70, 1365–77.CrossRefGoogle ScholarPubMed
Ranoux, D, Attal, N, Morain, F, Bouhassira, D (2008). Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol, 64, 274–83.CrossRefGoogle ScholarPubMed
Schaible, HG, Del Rosso, A, Matucci-Cerinic, M (2005). Neurogenic aspects of inflammation. Rheum Dis Clin North Am, 31, 77–101.CrossRefGoogle Scholar
Schaible, HG, Schmelz, M, Tegeder, I (2006). Pathophysiology and treatment of pain in joint disease. Adv Drug Deliv Rev, 58, 323–42.CrossRefGoogle ScholarPubMed
Schaible, HG, Richter, F, Ebersberger, A et al. (2009). Joint pain. Exp Brain Res, 196, 153–62.CrossRefGoogle ScholarPubMed
Siddiqui, MA (2007). The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence. Curr Opin Rheumatol, 19, 308–13.CrossRefGoogle ScholarPubMed
Singer, BJ, Silbert, PL, Dunne, JW, Song, S, Singer, KP. (2006). An open label pilot investigation of the efficacy of Botulinum toxin type A [Dysport] injection in the rehabilitation of chronic anterior knee pain. Disabil Rehabil, 28, 707–13.CrossRefGoogle ScholarPubMed
Singh, JA, Mahowald, ML, Kushnaryov, A, Goelz, E, Dykstra, D (2009a). Repeat injections of intra-articular botulinum toxin A for the treatment of chronic arthritis joint pain. J Clin Rheumatol, 15, 35–8.CrossRefGoogle ScholarPubMed
Singh, JA, Mahowald, ML, Noorbaloochi, S (2009b). Intra-articular botulinum toxin A for refractory shoulder pain: a randomized, double-blinded, placebo-controlled trial. Transl Res, 153, 205–16.CrossRefGoogle ScholarPubMed
Sycha, T, Samal, D, Chizh, B et al. (2006). A lack of antinociceptive or antiinflammatory effect of botulinum toxin A in an inflammatory human pain model. Anesth Analg. 102, 509–16.CrossRefGoogle ScholarPubMed
Voller, B, Sycha, T, Gustorff, B et al. (2003). A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A. Neurology, 61, 940–4.CrossRefGoogle ScholarPubMed
von Lindern, JJ (2001). Type A botulinum toxin in the treatment of chronic facial pain associated with temporo-mandibular dysfunction. Acta Neurol Belg, 101, 39–41.Google ScholarPubMed
von Lindern, JJ, Niederhagen, B, Berge, S, Appel, T (2003). Type A botulinum toxin in the treatment of chronic facial pain associated with masticatory hyperactivity. J Oral Maxillofac Surg, 61, 774–8.CrossRefGoogle Scholar
Wong, SM, Hui, AC, Tong, PY et al. (2005). Treatment of lateral epicondylitis with botulinum toxin: a randomized, double-blind, placebo-controlled trial. Ann Intern Med, 143, 793–7.CrossRefGoogle ScholarPubMed
Woolf, CJ, Costigan, M (1999). Transcriptional and posttranslational plasticity and the generation of inflammatory pain. Proc Natl Acad Sci USA, 96, 7723–30.CrossRefGoogle ScholarPubMed
Yuan, RY, Sheu, JJ, Yu, JM et al. (2009). Botulinum toxin for diabetic neuropathic pain a randomized double-blind crossover trial. Neurology, 72, 1473–8.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×